| Previous Close | 2.98 |
| Open | 3.02 |
| Volume | 310,657 |
| Avg. Volume (3M) | 651,556 |
| Market Cap | 112,039,208 |
| Price / Earnings (Forward) | 5.13 |
| Price / Sales | 0.750 |
| 52 Weeks Range | |
| Earnings Date | 16 Mar 2026 |
| Profit Margin | -191.50% |
| Operating Margin (TTM) | -55.31% |
| Diluted EPS (TTM) | 29.61 |
| Quarterly Revenue Growth (YOY) | -14.10% |
| Current Ratio (MRQ) | 0.110 |
| Operating Cash Flow (TTM) | -145.74 M |
| Levered Free Cash Flow (TTM) | -114.08 M |
| Return on Assets (TTM) | -28.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Agenus Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.13 |
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 33.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Panagora Asset Management Inc | 31 Dec 2025 | 163,148 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |